Loading clinical trials...
Loading clinical trials...
A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
Horizon Research Group, Inc.
Mobile, Alabama, United States
Dermatology Research Associates
Los Angeles, California, United States
Expresscare Medical
Los Angeles, California, United States
Park Avenue Dermatology, PA
Orange Park, Florida, United States
Skin Specialists, PC
Omaha, Nebraska, United States
Academic Dermatology Associates
Albuquerque, New Mexico, United States
Health Concepts
Rapid City, South Dakota, United States
Modern Research Associates, PLLC
Dallas, Texas, United States
K.Papp Clinical Research Inc.
Waterloo, Ontario, Canada
Innovaderm Research Inc
Montreal, Quebec, Canada
Start Date
February 16, 2011
Primary Completion Date
November 29, 2011
Completion Date
November 29, 2011
Last Updated
January 11, 2021
71
ACTUAL participants
CP-690,550 Ointment 1
DRUG
Vehicle 1
DRUG
CP-690,550 Ointment 2
DRUG
Vehicle 2
DRUG
Lead Sponsor
Pfizer
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions